Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair

Hawthorne, NY December 19, 2002 Acorda Therapeutics announced today that it has been awarded a two-year Phase 2 Small Business Technology Transfer (STTR) grant from the National Institutes of Health. The $980,000 grant will continue to fund collaborative research between Acorda and Drs. Allan Bieber and Moses Rodriguez of Mayo Clinic. The grant will fund research at Acorda and at Mayo Clinic to advance the development of a class of naturally occurring human IgM antibodiesfor further preclinical testing in multiple sclerosis (MS). Upon successful completion of the aims of the study, Acorda expects to file an IND (investigational new drug application) with the FDA to begin clinical testing of these antibodies.

When myelin, the "insulation" surrounding nerve fibers, is lost or damaged, the nerve loses its ability to transmit signals to and from the brain. This loss of myelin can result in varying levels of disability, such as cognitive deficits, difficulty in walking and fatigue.

Under the support of a Phase 1 STTR grant, Acorda and Mayo Clinic tested the two antibodies under study (sHIgM22 and sHIgM46) using a widely accepted animal model. Mice were injected with a virus that causes demyelination in the nervous system and then received treatment with the study antibodies after the onset of demyelination. The antibody treatment produced a robust remyelination in these mice.

"Current MS therapies work by slowing the progression of the disease but do not address the permanent demyelination that leads to the disabilities associated with that condition. The antibodies being studied act to stimulate the regrowth of myelin, thereby offering an entirely new type of therapeutic approach in the treatment of MS," said Eric Chojnicki, Ph.D., Acorda's Director of Product Development, and the principal investigator on the grant.

"Our results indicate that these antibodies are part of the normal immune response in humans that may help protec

Contact: Tierney Saccavino, Acorda Therapeutics
Porter Novelli

Page: 1 2

Related biology news :

1. Acorda Therapeutics acquires CeNeS neuregulin products
2. Acorda Therapeutics receives L.W. Freeman Award for Scientific Research
3. Acorda Therapeutics begins Phase 3 trials of Fampridine-SR for chronic spinal cord injury
4. The future of HIV therapeutics is brightening, according to Gladstone Institutes Director
5. Molecular therapeutics advance fight against brain cancer
6. Conflicting views on embryonic and adult stem cells complicate research in stem cell therapeutics
7. Critical therapeutics is awarded U.S. patents for methods to diagnose and treat inflammatory disease
8. Immerge biotherapeutics identifies miniature swine that do not transmit pig retrovirus to humans
9. Polymer gel holds promise for therapeutics delivery and tissue engineering
10. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
11. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative

Post Your Comments:

(Date:6/3/2019)... (PRWEB) , ... June 03, 2019 , ... Stay on ... biotech, medical device and food industries. Access to all webinars is free, so be ... relevant in your field! , Visit http://www.xtalks.com to see our upcoming webinars: ...
(Date:5/31/2019)... ... May 30, 2019 , ... Researchers ... Mayo Clinic, have documented significant differences in the prevalence of hereditary genetic mutations, ... compared to non-Hispanic White women. Results will be presented at the 2019 American ...
(Date:5/31/2019)... ... May 31, 2019 , ... The OilComm ... Houston, TX, announced today that Ben Reiter, Senior Writer at Sports Illustrated and ... October 3rd.     , Reiter predicted the Houston Astros would win the MLB championship ...
Breaking Biology News(10 mins):
(Date:5/21/2019)... Ethiopia (PRWEB) , ... May 21, 2019 , ... ... Brauerei in Berlin (VLB) today officially opened the inaugural Africa Brewing Conference dedicated ... and malting industry in Africa. The event, which is supported through a partnership ...
(Date:5/14/2019)... HARBOR TOWNSHIP, N.J. (PRWEB) , ... May 13, ... ... manufacturer of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical ... completely new Heliumleak.com company website. The redesigned website aims to improve LDA’s ability ...
(Date:5/7/2019)... ... 06, 2019 , ... "The new Liquid Nitrogen Best Practices ... asked to store cellular products being used in adoptive therapy research and ... leaders, who have shared their expertise in building and managing facilities to support ...
(Date:5/2/2019)... ... April 30, 2019 , ... ... 9001:2015 standard, REPROCELL USA Inc. has demonstrated its ability to provide various ... Inc. aims to enhance customer satisfaction through the effective implementation of its ...
Breaking Biology Technology:
Cached News: